君实生物：JS212临床试验获FDA批准

Core Viewpoint - Junshi Biosciences (688180) announced on December 14 that it has received approval from the U.S. Food and Drug Administration (FDA) for its clinical trial application for the EGFR/HER3 bispecific antibody-drug conjugate (code: JS212) for the treatment of advanced solid tumors [1] Group 1 - The FDA approval allows Junshi Biosciences to proceed with clinical trials for JS212, which is designed to treat advanced malignant solid tumors [1] - JS212 is a recombinant humanized bispecific antibody targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3) [1] - The drug aims to address the treatment needs for patients with advanced solid tumors, indicating a potential advancement in cancer therapy [1]